Real-Time Imaging Visibility in Phase I Trials with Aperis
How Aperis gives sponsors continuous visibility of imaging data throughout a Phase I study.
Gastroenterology 
Women’s Health 
Dr Alex Menys
CSO
| Published | January 2025 |
|---|---|
| Category | Platform & Technology |
| Therapy Areas | Gastroenterology, Women’s Health |
| Read Time | <1 minute |
Related articles
Overview
This article shares perspective from the Fidēs team on early-phase imaging. Replace this placeholder with the full article body — the content is fully editable as blocks.
What this means in practice
Practical implications for sponsors designing imaging into early-phase programs.
The Fidēs approach
How Fidēs embeds imaging into scientific decision-making from protocol design onwards.
The thinking behind Aperis — built for how scientists actually interrogate imaging mid-study.
Read more
Functional cardiac motion as an imaging endpoint in early cardiovascular development.
Read more
The Fidēs team will be at ECCO 2025 in Stockholm — book a meeting to talk early-phase GI imaging.
Read more
The decision problem at the heart of IBD trials, and how imaging can de-risk it earlier.
Read more
Rethinking response assessment in oncology with additive, mechanistically relevant imaging endpoints.
Read more
Why motion and motility are powerful, under-used imaging endpoints in early-phase trials.
Read more
Fidēs Imaging opens its doors as a science-first imaging Core Lab focused on early-phase clinical development.
Read more